CMS will truncate the performance period to the first 9 months of data for the Medicare Part B claims, MIPS clinical quality measure (CQM), and electronic clinical quality measure (eCQM) collection types for measure Q111: Pneumococcal Vaccination Status for Older Adults.

At the October 20, 2021 meeting, the Advisory Committee on Immunization Practices (ACIP) approved, by majority vote, to update the pneumococcal vaccine recommendations. The revised recommendation no longer aligns with the current posted measure specifications for the Medicare Part B claims, MIPS CQM, and eCQM collection types, as numerator compliance is achieved through administration or previous receipt of either the pneumococcal conjugate vaccine (PCV) 13 or pneumococcal polysaccharide vaccine (PPSV23) vaccine (or both). ACIP now recommends:

  • Adults 65 and older with no previous receipt of or unknown status of vaccination should receive the PCV20 or PCV15 vaccine.
    • If PCV15 is administered, this should be followed by a dose of PPSV23.
  • Adults aged 19 – 64 with certain underlying conditions of risk-factors with no previous receipt of or unknown status of vaccination should receive the PCV20 or PCV15 vaccine.
    • If PCV15 is administered, this should be followed by a dose of PPSV23.

Therefore, CMS is truncating the performance period for the Medicare Part B claims, MIPS CQM, and eCQM collection types for this measure to the first 9 months of data in accordance with § 414.1380(b)(1)(vii)(A). MIPS eligible clinicians do not need to submit any additional documentation, and CMS will assess the measure for these collection types based upon the first 9 months of data.

Back to top